Michael Prevoznik - Quest Diagnostics Senior Vice President General Counsel
| DGX Stock | USD 137.55 0.85 0.62% |
President
Mr. Michael E. Prevoznik is Senior Vice President, General Counsel of the Company. Mr. Prevoznik joined the Company as Vice President and General Counsel in August 1999. In 2003, he assumed responsibility for governmental affairs. From 1999 until April 2009, Mr. Prevoznik also had responsibility for the Company Compliance Department. In addition, from April 2011 to January 2017, he had management responsibility for the Company diagnostic information services activities outside the U.S., and from April 2011 to January 2013, he had management responsibility for the Company clinical trials business. Prior to joining the Company, Mr. Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline Beecham compliance activities worldwide. since 2003.
| Age | 62 |
| Tenure | 21 years |
| Address | 500 Plaza Drive, Secaucus, NJ, United States, 07094 |
| Phone | 973 520 2700 |
| Web | https://www.questdiagnostics.com |
Quest Diagnostics Management Efficiency
The company has Return on Asset of 0.0621 % which means that on every $100 spent on assets, it made $0.0621 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1462 %, implying that it generated $0.1462 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.14 in 2024. Return On Capital Employed is likely to drop to 0.10 in 2024. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.99 in 2024, whereas Total Assets are likely to drop slightly above 8.5 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Neal DO | Aclaris Therapeutics | 54 | |
| Samantha Kwok | Prenetics Global | N/A | |
| Peter Donato | Neuronetics | 47 | |
| Gene Stahl | Prenetics Global | N/A | |
| Veronica Foley | Prenetics Global | N/A | |
| Luciano Bonanni | Fonar | 69 | |
| Darcy Falardeau | Prenetics Global | N/A | |
| Darren Ruhr | Prenetics Global | N/A | |
| Douglas Evasiuk | Prenetics Global | N/A | |
| Anthony Pui | Neuronetics | N/A | |
| Yelena Tropsha | Neuronetics | 57 | |
| Olivier Jarry | DarioHealth Corp | 63 | |
| Carl Raimond | Olink Holding AB | 53 | |
| Steve MacKinnon | Neuronetics | N/A | |
| Niels Espeland | Prenetics Global | N/A | |
| MD DO | Aclaris Therapeutics | 54 | |
| Carey Ford | Prenetics Global | N/A | |
| Gregory Harper | Neuronetics | 57 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0621 |
Quest Diagnostics Leadership Team
Elected by the shareholders, the Quest Diagnostics' board of directors comprises two types of representatives: Quest Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quest. The board's role is to monitor Quest Diagnostics' management team and ensure that shareholders' interests are well served. Quest Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quest Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Plewman, Senior Services | ||
| Gail Wilensky, Independent Director | ||
| Kristin Esq, Senior Officer | ||
| Stephen Rusckowski, CEO and President Director and Member of Executive Committee | ||
| Wright Lassiter, Independent Director | ||
| Gary Pfeiffer, Independent Director | ||
| Vicky Gregg, Independent Director | ||
| Cecilia McKenney, Senior Officer | ||
| Helen Torley, Independent Director | ||
| Michael Prevoznik, Senior Vice President General Counsel | ||
| Tracey Doi, Independent Director | ||
| John Ziegler, Independent Director | ||
| Karthik Kuppusamy, Senior Solutions | ||
| John Baldwin, Independent Director | ||
| Jon Cohen, Senior Vice President Chief Medical Officer | ||
| Catherine Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing | ||
| Manuel Mendez, Senior Vice President Chief Commercial Officer | ||
| Gabrielle Wolfson, Senior Vice President and Chief Information and Digital Officer | ||
| Carrie Manner, Senior Vice President - Advanced Diagnostics | ||
| Sam Samad, Executive CFO | ||
| Dermot Shorten, MA Strategy | ||
| Jenne Britell, Independent Director | ||
| Shawn Bevec, Executive Director Investor Relations | ||
| Dan Haemmerle, Executive Director - Investor Relations | ||
| Timothy Main, Independent Director | ||
| Michael Deppe, Vice President Corporate Controller and Chief Accounting Officer and Principal Accounting Officer | ||
| Everett Cunningham, Senior Vice President - Commercial | ||
| Mark Guinan, Chief Financial Officer, Executive Vice President | ||
| Daniel Stanzione, Non-Executive Chairman of the Board | ||
| Gary Samuels, Senior Officer | ||
| Denise Morrison, Independent Director | ||
| James Davis, Executive Vice President, General Diagnostics | ||
| Jeffrey Leiden, Independent Director | ||
| Timothy Ring, Lead Independent Director |
Quest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quest Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0621 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 19.32 B | ||||
| Shares Outstanding | 111.06 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 91.76 % | ||||
| Number Of Shares Shorted | 2.55 M | ||||
| Price To Earning | 14.57 X |
Pair Trading with Quest Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Quest Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Quest Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving against Quest Stock
| 0.47 | MCD | McDonalds Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Quest Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Quest Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Quest Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Quest Diagnostics Incorporated to buy it.
The correlation of Quest Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Quest Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Quest Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Quest Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Quest Diagnostics Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Quest Diagnostics information on this page should be used as a complementary analysis to other Quest Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Quest Stock analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Quest Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quest Diagnostics. If investors know Quest will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quest Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.868 | Dividend Share 2.84 | Earnings Share 7.49 | Revenue Per Share 82.607 | Quarterly Revenue Growth (0.02) |
The market value of Quest Diagnostics is measured differently than its book value, which is the value of Quest that is recorded on the company's balance sheet. Investors also form their own opinion of Quest Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Quest Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quest Diagnostics' market value can be influenced by many factors that don't directly affect Quest Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quest Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Quest Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quest Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.